News archive
- Headquarters EATRIS will come to the Netherlands
- Impulse for translational research in the Netherlands and in Europe (press release ZonMw and CTMM)
- Immunotherapy against skin cancer
- An AMC researcher has discovered that seeded melanoma, an agressive form of skin cancer that is difficult to treat, can be fought by artificially inducing a different skin condition: vitiligo.
- Competition for innovative business plans
- Entrepreneurs who want to start an innovative business are invited to enter business plan competition New Venture.
- Marcel Levi proposed as successor Louise Gunning
- Prof. Dr. Marcel Levi has been proposed by the Supervisory Board of the Academic Medical Center (AMC) to succeed prof. dr. Louise Gunning as President of the Board of Directors.
- OncoMethylome Appoints Dr. Jan Groen as CEO
- OncoMethylome Sciences SA announced today that its board of directors has named Dr. Jan Groen to serve as the company's chief executive officer.
- AMC research shows that HIV subverts innate signaling
- HIV, the virus that causes aids, uses the immune system to multiply itself. This unexpected discovery by the group of prof. dr. Teunis Geijtenbeek of the Center for Experimental and Molecular Medicine in the AMC was published this week in Nature Immunology.
- AMC to lead artificial pancreas programme
- Amsterdam University's medical centre said on Tuesday it is to lead a European project to develop an artificial pancreas for people with type 1 diabetes. The consortium, made up of seven academic institutions and five private companies, will work on the project for the next four years. It has been given €10.5m in funding by the European Commission.
- Agendia Launches BluePrint(TM) Expanding Breast Cancer Product Offering
- Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes. This new service is based on an 80-gene signature that identifies the basal-like, luminal-like, and HER2 molecular subtypes in breast cancer tumors.
- Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
- Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites.
- AMOLF opens new laboratory
- AMOLF’s new laboratory on the Science Park Amsterdam was opened by Jos Engelen, chairman of the Governing Board of the Netherlands Organisation for Scientific Research (NWO)
- Abbott completes acquisition of Solvay Pharmaceuticals
- After triggering and only recently resolving some anti-trust concerns in Europe, Abbott announced that it has completed its $6.2 billion acquisition of Solvay Pharmaceuticals, “providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott’s presence in key global emerging markets.”
- 8200 New innovation vouchers available in 2010
- The Dutch Ministry of Economic Affairs issued 6200 public and 2000 private new innovationvouchers. The vouchers can already be applied for at Agentschap NL
- Cooperation agreement signed for Life Sciences Innovation Platform in Flevoland
- The platform aims to create a framework in which development and innovation within the region have a better chance of success.
- Dutch biotech rising in world rankings
- 20 January 2010 - The Life Sciences & Health Innovation Program (LSH) and the Nyenrode Life Sciences & Healthcare Institute presented the first Biotech Outlook, in which the Dutch cluster in the field of ‘red’ biotech was compared with the international leaders (seven clusters).
- Sanquin - Crucell agreement
- Solvay Pharmaceuticals acquires Innogenetics
- 9 September 2008-Solvay Pharmaceuticals S.A. succeeded to acquire Innogenetics N.V., a Belgian-based biotechnological company.
- Roche pulls out of a diabetes drug alliance with Ipsen
- Swiss drugmaker Roche has dropped development of diabetes treatment taspoglutide, ending its partnership with French drugmaker Ipsen and pushing Ipsen's shares as much as 4 percent lower.
- Genzyme Sells Diagnostics Business to Sekisui Chemical
- Genzyme Corporation has completed the sale of its diagnostic products business to Sekisui Chemical for $265 million in cash.
- BIO International Convention 2008
- 17-21 June 2008-20,000 visitors and 70 countries attended the BIO International Convention in San Diego.
- Monitor Life Sciences Amsterdam Region Published
- The research and statistics department of the city of Amsterdam has published a first report on the Life Sciences sector in the Amsterdam region. The investigation was requested by the AIM.
- International Talent meets Dutch life Sciences
- 4 February 2008-In participation with the AIM, Hyphen Project Management is organising a NEW international event offering international talents in the life science sector the possibility to explore the many job and career opportunities the Netherlands is offering.
- RSS feed function installed
- We recently installed a RSS feed function. You can subscribe by clicking the RSS icon on individual pages or topics.
- Fornix posts 12% higher net profit
- 19 February 2008-Right after finishing the last clinical tests on it's new wedicine Oralgen®, Fornix anounces a 12% higher net profit over the last year.
- New EU project to develop catalogue of genetic variation
- Creating a catalogue of genetic variation and its impact on our health is the goal of the EU-funded GEN2PHEN (Genotype-to-phenotype databases: a holistic solution) project, which has just got underway under the Seventh Framework Programme (FP7).
- Sign in now for the Amsterdam BioMed Cluster Life Sciences Café on March 13!
- Genmab and Pepscan to identify human antibodies against intractable targets
- Genmab A/S (OMX: GEN) and Pepscan today announced the start of a research collaboration aimed at identifying fully human monoclonal antibodies against intractable disease targets.
- Amsterdam launches BioBusiness Summer School
- The BioBusiness PhD summer school offers a two-week programme introducing PhD students and post-docs to the international field of biomedical business. Lectures by experts in the field and site visits to a range of companies are scheduled, next to a social programme.
- DSM and Crucell Announce PER.C6® Technology Milestone.
- 11 March 2008-DSM Biologics Dutch biotechnology company Crucell N.V. an-nounced today that another important milestone has been achieved with the PER.C6® technology platform for the production of monoclonal antibodies and recombinant proteins.
- Genzyme Announces Presentation of New Positive Data on Carticel®
- 10 March 2008-A large, multicenter, observational study by Genzyme's revealed the improvement in knee function by its new drug Carticel® is sustainable in 90 percent of the patients treated successfully.
- Celera and Leiden University Medical Center Discover Genetic Markers Associated with Deep Vein Thrombosis
- 18 March 2008-Findings from Three Case-Control Studies Involving More Than 8,000 Individuals to Improve Identification of High Risk Individuals
- BAC and Octapharma to develop custom ligand for recombinant plasma protein
- BAC BV, announced that it has entered into a collaboration with Octapharma AG. The objective of the collaboration is to discover and develop a custom CaptureSelect® ligand for the purification of a recombinant Factor IX product, developed by Octapharma.
- Multidisciplinary CNCR-team receives a ZonMW TOP grant
- A multidisciplinary CNCR-team receives a ZonMW TOP grant to apply new strategies from bioinformatics and systems biology to identify gene networks implicated in cognitive abilities.
- Promising clinical data from Kiadis Pharma’s lead product ATIR presented by NIH investigators
- Biopharmaceutical company Kiadis Pharma announces the presentation of results obtained so far in a physician initiated clinical study for ATIR™. At the EBMT meeting in Florence Dr. Mielke will present results of the ongoing phase II clinical trial of ATIR™ in matched allogeneic transplantations that is running at the NIH under an FDA approved IND.
- Trial: popular cholesterol drug fails to improve heart disease
- 31 March 2008-A study by the Dutch scientist John Kastelein revealed the drug Vytorin does not have any effect on plaque buildup, even though it dramatically lowered LDL. This is bad news for the producers Schering-Plough and Merck. The drug has a yearly revenue of five bilion in the US only.
- Large investment in health care innovations
- The ministry of economic affairs announces it will invest more than 30 million Euro over a four year period on the Innovation programme Life Sciences and Healthcare. The programme aims at making the Netherlands a hotspot for healthcare-relate companies offering them plenty of opportunities to work and grow.
- Amsterdam BioMed Cluster in top three of "Pieken in de Noordvleugel" projects
- 2 April 2008-Minister of Economic Affairs Maria van der Hoeven announced the winning projects within its “Pieken in de Delta” economic development programme. “Amsterdam BioMed in Business!” ended in the top three of winning projects submitted by the region “Noordvleugel”.
- Today! Launch new innovation programme for Life Sciences and Health
- 9 April 2008-The Ministry of Economic Affairs will invest 30M Euro over a four year period in Life Sciences and Health. This innovation programme, a concerted action of knowledge institutes and companies, aims to give this promising sector a serious boost.
- Geneticom offers preventive DNA tests
- Geneticom has this week begun with offering genetic tests to private customers. The tests are meant to indicate long-term risks on heritable diseases. The company is mediating between customers and companies offering tests, and does not perform the tests, which are done at a Dutch company specialized in genetic testing.
- AMOLF launches website for technology transfer
- 21 November 2011 – FOM institute AMOLF has launched an online store where it offers its research facilities and expertise for high tech SMEs.
